simpleblogdescriptionhellog

H.U. Group Holdings President Shigekazu Takeuchi / Ask the top [2022/01/27]

H.U. Group Holdings President Shigekazu Takeuchi / Ask the top [2022/01/27]

27 January 2022 | 1:50 am

HU Group Holdings, which owns Fujirebio, a major clinical testing drug company, and SRL, the largest contracted clinical testing company. Demand for PCR tests and other products is expected to grow sharply in response to the Corona disaster, and the fiscal year ending March 2022 is expected to reach record highs in sales and profits for the second consecutive year. However, since our main inspection-related business has low growth in the medium to long term, we have invested 85 billion yen to operate a base that automates inspection operations in Tokyo. On the other hand, we are stepping up our efforts toward “post-corona” by investing management resources in highly profitable and growth-promising businesses such as clinical test reagents and contract development and manufacturing. We invite President Shigekazu Takeuchi to approach our growth strategy. You can see the continuation in the main story below.

Leave a Reply